PDS Biotechnology (NASDAQ:PDSB) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of PDS Biotechnology (NASDAQ:PDSB) from a hold rating to a sell rating in a research note published on Saturday morning.

Several other equities analysts also recently commented on PDSB. HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of PDS Biotechnology in a report on Wednesday, April 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of PDS Biotechnology in a research note on Friday, July 17th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Up 1.7%

Shares of PDSB opened at $0.69 on Friday. The business’s 50 day moving average is $0.93 and its 200 day moving average is $0.89. The company has a market capitalization of $38.74 million, a PE ratio of -1.03 and a beta of 1.59. PDS Biotechnology has a 12-month low of $0.51 and a 12-month high of $1.55. The company has a current ratio of 2.26, a quick ratio of 2.26 and a debt-to-equity ratio of 2.73.

PDS Biotechnology (NASDAQ:PDSB) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. Research analysts expect that PDS Biotechnology will post -0.52 earnings per share for the current fiscal year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC purchased a new stake in shares of PDS Biotechnology during the 4th quarter worth approximately $2,182,000. Geode Capital Management LLC grew its holdings in shares of PDS Biotechnology by 8.0% in the fourth quarter. Geode Capital Management LLC now owns 520,398 shares of the company’s stock valued at $401,000 after purchasing an additional 38,399 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of PDS Biotechnology by 116.1% in the third quarter. Squarepoint Ops LLC now owns 291,627 shares of the company’s stock valued at $295,000 after purchasing an additional 156,662 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of PDS Biotechnology by 25.0% in the first quarter. Renaissance Technologies LLC now owns 220,800 shares of the company’s stock valued at $134,000 after purchasing an additional 44,100 shares in the last quarter. Finally, Commonwealth Equity Services LLC increased its position in PDS Biotechnology by 117.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 196,797 shares of the company’s stock worth $151,000 after purchasing an additional 106,300 shares during the last quarter. Hedge funds and other institutional investors own 26.84% of the company’s stock.

PDS Biotechnology Company Profile

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.